MA45714A - Activateurs de glucokinase et leurs procédés d'utilisation - Google Patents

Activateurs de glucokinase et leurs procédés d'utilisation

Info

Publication number
MA45714A
MA45714A MA045714A MA45714A MA45714A MA 45714 A MA45714 A MA 45714A MA 045714 A MA045714 A MA 045714A MA 45714 A MA45714 A MA 45714A MA 45714 A MA45714 A MA 45714A
Authority
MA
Morocco
Prior art keywords
methods
glucokinase activators
glucokinase
activators
Prior art date
Application number
MA045714A
Other languages
English (en)
Inventor
Peter T W Cheng
Mark Liu
Wei Meng
Bei Wang
Rulin Zhao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA45714A publication Critical patent/MA45714A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA045714A 2016-07-22 2017-07-21 Activateurs de glucokinase et leurs procédés d'utilisation MA45714A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662365520P 2016-07-22 2016-07-22

Publications (1)

Publication Number Publication Date
MA45714A true MA45714A (fr) 2019-05-29

Family

ID=59501613

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045714A MA45714A (fr) 2016-07-22 2017-07-21 Activateurs de glucokinase et leurs procédés d'utilisation

Country Status (7)

Country Link
US (1) US10604541B2 (fr)
EP (1) EP3487862A1 (fr)
JP (1) JP7072557B2 (fr)
KR (1) KR102513342B1 (fr)
CN (1) CN109715637B (fr)
MA (1) MA45714A (fr)
WO (1) WO2018017910A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121263182A (zh) * 2023-06-06 2026-01-02 华领医药技术(上海)有限公司 用于认知障碍和神经退行性疾病的葡萄糖激酶激活剂

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594113A (en) 1988-06-23 1997-01-14 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (fr) 1995-10-05 1997-04-10 Warner-Lambert Company Procede de traitement et de prevention des inflammations et de l'atherosclerose
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
KR20020079988A (ko) 2000-03-08 2002-10-21 메타베이시스 테라퓨틱스, 인크. 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
WO2005025504A2 (fr) 2003-09-12 2005-03-24 Kemia, Inc. Modulateurs de l'activite de la calcitonine et de l'amyline
PL2060266T3 (pl) 2004-03-17 2012-01-31 7Tm Pharma As Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych
PT1756096E (pt) 2004-05-03 2009-10-16 Hoffmann La Roche Derivados de indolilo como moduladores do receptor x do fígado
JP2008502658A (ja) 2004-06-17 2008-01-31 ノボ ノルディスク アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
CN101490064B (zh) * 2006-07-06 2012-10-10 百时美施贵宝公司 新颖葡萄糖激酶活化剂及其使用方法
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
GB0619325D0 (en) 2006-09-30 2006-11-08 Univ Strathclyde New compounds
AU2008223348A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
WO2008154563A1 (fr) 2007-06-11 2008-12-18 Bristol-Myers Squibb Company Activateurs de la glucokinase de type phénylamide à substitution 1,3 hydroxy
CN101808995A (zh) 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
MX2010001784A (es) 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
WO2010029300A1 (fr) 2008-09-12 2010-03-18 Biolipox Ab Composés bis-aromatiques pour utilisation dans le traitement de l’inflammation
WO2010107610A1 (fr) 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Méthode de traitement du diabète et des états pathologiques correspondants par thérapie combinatoire et compositions contenant de tels composés
US20110021570A1 (en) 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
WO2011130459A1 (fr) * 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US20130197229A1 (en) 2010-10-13 2013-08-01 Christopher Matthews Method of making azaindazole derivatives
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3191453B1 (fr) 2014-09-09 2019-10-23 Bristol-Myers Squibb Company Modulateurs des récepteurs gpr120 à base d'acide phényl-(aza)cycloalkylcarboxylique

Also Published As

Publication number Publication date
JP7072557B2 (ja) 2022-05-20
KR20190033571A (ko) 2019-03-29
US20190233449A1 (en) 2019-08-01
WO2018017910A1 (fr) 2018-01-25
CN109715637A (zh) 2019-05-03
CN109715637B (zh) 2022-04-05
JP2019523253A (ja) 2019-08-22
KR102513342B1 (ko) 2023-03-22
EP3487862A1 (fr) 2019-05-29
US10604541B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3510040A4 (fr) Inhibiteurs d'éctonucléotidase et leurs procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA44490A (fr) Adhésifs biocompatibles et leurs procédés d'utilisation
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3416634A4 (fr) Agents immunomodulateurs et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3377612A4 (fr) Expression fonctionnelle de monooxygénases et procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EP3303634A4 (fr) Variants de cas9 et procédés d'utilisation associés
EP3435956A4 (fr) Compositions photo-stabilisées et leurs procédés d'utilisation
EP3368538A4 (fr) Inhibiteurs de la kinase wee 1 et leurs procédés de fabrication et d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
EP3352774A4 (fr) Compositions de flavonoïdes et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation